Anaemia (cancer-treatment induced) - erythropoiesis-stimulating agents (epoetin and darbepoetin) (inc rev TA142): evaluation report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal

01 - Overview prepared by NICE

02 - Assessment Report prepared by Peninsula Technology Assessment Group

03 - Comments on the Assessment Report - Amgen

04 - Comments on the Assessment Report - Target Ovarian

05 - Comments on the Assessment Report -  Royal College Pathologists and BSCH

06 - Comments on the Assessment Report - Royal College of Nursing

07 - Comments on the Assessment Report - Janssen

08 - Comments on the Assessment Report - Department of Health

09 - Response to comments on the Assessment Report prepared by Peninsula Technology Assessment Group

10 - Executive summary of technology manufacturer’s submission - Amgen

11 - Executive summary of technology manufacturer’s submission - Sandoz

12 - Consultee submission - Myeloma UK

This page was last updated: 15 April 2014